Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

Trial Profile

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Ivacaftor/tezacaftor (Primary) ; Ivacaftor/tezacaftor/VX-659 (Primary) ; VX 659 (Primary) ; Deutivacaftor; Ivacaftor; Tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 18 Oct 2018 According to a Vertex Pharmaceuticals media release, primary endpoint (Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)) has been met.
    • 18 Oct 2018 According to a Vertex Pharmaceuticals Media Release, data presented at North American Cystic Fibrosis Conference (NACFC).
    • 18 Oct 2018 Results presented in a Vertex Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top